Rapid hemodilution induced by desmopressin after erythropoietin administration in humans

We have shown that treatment with desmopressin has a very effective hemodilution effect in healthy humans. These results led us to suggest the possible role of desmopressin to mask blood doping in sports. Based on our results, the World Anti-Doping Agency included the desmopressin in the 2011 List of Prohibited Substances and Methods. On this occasion, the aim of our study was to test the desmopressin-induced hemodilution after rHuEpo administration in humans. This was an intra-subject, crossover study in which five physically active males acted as their own controls. A basal blood sample was taken on their first visit to the laboratory. The next day, the subjects began the treatment. They received a subcutaneous rHuEpo injection three times/week for a two-week period. On the second visit to the laboratory, seventeen days later, a blood sample was taken. Thereafter, the subjects received an oral dose of 4.3 μg/kg of desmopressin and were instructed to ingest 1.5 liters of mineral water during the following fifteen minutes. Three hours after the water ingestion a second blood sample was obtained. The samples were analyzed for hematocrit (HCT), hemoglobin (Hb), reticulocytes (Ret%) and OFF Hr-Score. We found significantly higher HCT, Hb and Ret% levels after rHuEpo administration. Administration of desmopressin significantly decreased the HCT and Hb values but we did not find significant changes in Ret%. The values of the OFF Hr-Score also decreased after treatment with desmopressin. Desmopressin has a very effective hemodilution effect after rHuEpo administration and significantly modifies the hematological values measured by the anti-doping authorities to detect blood doping. We consider that these results reinforce the conclusions reported in our first study and confirm that desmopressin is a very effective masking agent for blood doping.This work was supported by grants SAF2008-00270; SAF2009-08334; BFU2007-65803/BFI; from the Spanish Ministry of Education and Science (MEC); PROMETEO/2010/074 from the Consellería de Educación de la Generalitat Valenciana. ISCIII2006-RED13-027 from the “Red Temática de investigación cooperativa en envejecimiento y fragilidad (RETICEF)”, EU Funded COSTB35 and DPS2008-06968 from Spanish Ministry of Innovation and Science. This study has been co-financed by FEDER funds from the European Union

Pathophysiology of atrial fibrillation in endurance athletes: an overview of recent findings

Sin financiación6.784 JCR (2016) Q1, 11/155 Medicine, General and Internal1.738 SJR (2016) Q1, 215/2886 Medicine (miscellaneous)No data IDR 2016UE

Acute myocardial infarction: 'telomerasing' for cardioprotection

Reactivating the telomerase gene through gene therapy after acute myocardial infarction (AMI) has been recently reported to improve survival in mice. Given that regular physical exercise also activates this gene, therapeutic and lifestyle interventions targeting telomerase need to be explored as possible additions to the current armamentarium for myocardial regeneration.9.292 JCR (2015) Q1, 17/289 Biochemistry & mollecular biology, 17/187 Cell biology, 8/124 Medicine, research & experimentalUE

‘Mitotherapy’ for heart failure

Abnormalities in mitochondrial dynamics along with those for the molecular mediators involved are presently being viewed with increased interest in the field of cardiovascular disease. Recent research highlights OPA1, a dynamin-like GTPase mediating mitochondrial fusion, as well as the 'mitoproteases' OMA1 and YME1L, as potential therapeutic targets against heart failure.Sin financiación10.732 JCR (2016) Q1, 12/290 Biochemistry and Molecular Biology, 14/190 Cell Biology, 6/128 Medicine, Research and Experimental5.052 SJR (2016) Q1, 25/423 Molecular Biology, 6/183 Molecular MedicineNo data IDR 2016UE

Cardiometabolic non-response to aerobic exercise: identifying subclinical ischemic coronary disease

Sin financiación5.864 JCR (2019) Q1, 18/138 Cardiac & Cardiovascular Systems1.459 SJR (2019) Q1, 58/362 Cardiology and Cardiovascular Medicine; Q2, 36/104 EpidemiologyNo data IDR 2019UE

Time for doctors to practise what they preach and preach what they practise

Sin financiación6.557 JCR (2016) Q1, 3/81 Sport Sciences3.518 SJR (2016) Q1, 56/2886 Medicine (miscellaneous), 1/280 Orthopedics and Sports Medicine, 1/195 Physical Therapy, Sports Therapy and Rehabilitation, 1/127 Sports ScienceNo data IDR 2016UE

Exercise medicine education should be expanded

Sin financiación7.867 JCR (2017) Q1, 1/81 Sport Sciences3.232 SJR (2017) Q1, 66/2878 Medicine (miscellaneous), 3/285 Orthopedics and Sports Medicine, 3/201 Physical Therapy, Sports Therapy and Rehabilitation, 3/127 Sports ScienceNo data IDR 2017UE

The hMTH1 paradox: antioxidants recommended in cancer?

3.111 JCR (2014) Q2, 62/167 Genetics & heredity, 26/87 ToxicologyUE